(Q38591835)

4 September 2017

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road (English)

1 reference

4 September 2017

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26399658%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Christopher J Caunt

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26399658%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Matthew J Sale

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26399658%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Paul D Smith

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26399658%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

1 September 2015

1 reference

4 September 2017

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26399658%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26399658%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

577-592

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26399658%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26399658%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc4000

3 June 2020

exact match

0 references

cites work

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

1 reference

Ras oncogenes: split personalities

31 March 2020

1 reference

Cell fate decisions are specified by the dynamic ERK interactome

31 March 2020

1 reference

The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition

31 March 2020

1 reference

Tumour cell survival signalling by the ERK1/2 pathway

31 March 2020

1 reference

MEK genomics in development and disease

31 March 2020

1 reference

The ground state of embryonic stem cell self-renewal

31 March 2020

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

Targeting the mitogen-activated protein kinase cascade to treat cancer

31 March 2020

1 reference

Targeting the RAF-MEK-ERK pathway in cancer therapy

31 March 2020

1 reference

Targeting RAS-ERK signalling in cancer: promises and challenges

31 March 2020

1 reference

A synthetic inhibitor of the mitogen-activated protein kinase cascade

31 March 2020

1 reference

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

31 March 2020

1 reference

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

31 March 2020

1 reference

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

31 March 2020

1 reference

Mutations of the BRAF gene in human cancer

31 March 2020

1 reference

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

31 March 2020

1 reference

Vemurafenib: the first drug approved for BRAF-mutant cancer

31 March 2020

1 reference

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

31 March 2020

1 reference

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

31 March 2020

1 reference

Scaffold proteins: hubs for controlling the flow of cellular information

31 March 2020

1 reference

The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells

31 March 2020

1 reference

Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling

31 March 2020

1 reference

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells

31 March 2020

1 reference

Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression

31 March 2020

1 reference

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction

31 March 2020

1 reference

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

31 March 2020

1 reference

Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer

31 March 2020

1 reference

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

31 March 2020

1 reference

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors

31 March 2020

1 reference

Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation

31 March 2020

1 reference

ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest

31 March 2020

1 reference

MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression

31 March 2020

1 reference

Role of mitogen-activated protein kinase kinase kinases in signal integration

31 March 2020

1 reference

MEK1/2 dual-specificity protein kinases: structure and regulation

31 March 2020

1 reference

Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues.

31 March 2020

1 reference

Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes

31 March 2020

1 reference

Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion

31 March 2020

1 reference

A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal

31 March 2020

1 reference

Mek2 is dispensable for mouse growth and development

31 March 2020

1 reference

Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta

31 March 2020

1 reference

Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells

31 March 2020

1 reference

Transformation of mammalian cells by constitutively active MAP kinase kinase

31 March 2020

1 reference

BRAF mutation predicts sensitivity to MEK inhibition

31 March 2020

1 reference

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

31 March 2020

1 reference

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

31 March 2020

1 reference

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

31 March 2020

1 reference

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

31 March 2020

1 reference

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

31 March 2020

1 reference

RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation

31 March 2020

1 reference

Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome

31 March 2020

1 reference

Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines.

31 March 2020

1 reference

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy

31 March 2020

1 reference

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma

31 March 2020

1 reference

MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas.

31 March 2020

1 reference

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

31 March 2020

1 reference

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking

31 March 2020

1 reference

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

31 March 2020

1 reference

C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

31 March 2020

1 reference

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

31 March 2020

1 reference

Identification of a novel inhibitor of mitogen-activated protein kinase kinase

31 March 2020

1 reference

Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway

31 March 2020

1 reference

Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1.

31 March 2020

1 reference

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

31 March 2020

1 reference

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

31 March 2020

1 reference

Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors

31 March 2020

1 reference

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

31 March 2020

1 reference

Thermodynamics of nucleotide and non-ATP-competitive inhibitor binding to MEK1 by circular dichroism and isothermal titration calorimetry

31 March 2020

1 reference

Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.

31 March 2020

1 reference

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

31 March 2020

1 reference

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

31 March 2020

1 reference

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors

31 March 2020

1 reference

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

31 March 2020

1 reference

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

31 March 2020

1 reference

Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity

31 March 2020

1 reference

Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent

31 March 2020

1 reference

Molecular pathways: CDK4 inhibitors for cancer therapy

31 March 2020

1 reference

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

31 March 2020

1 reference

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma

31 March 2020

1 reference

V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a

31 March 2020

1 reference

Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo

31 March 2020

1 reference

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

31 March 2020

1 reference

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

31 March 2020

1 reference

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

31 March 2020

1 reference

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling

31 March 2020

1 reference

Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).

31 March 2020

1 reference

Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models

31 March 2020

1 reference

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

31 March 2020

1 reference

STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.

31 March 2020

1 reference

Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma

31 March 2020

1 reference

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

31 March 2020

1 reference

Improved survival with MEK inhibition in BRAF-mutated melanoma

31 March 2020

1 reference

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors

31 March 2020

1 reference

Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma

31 March 2020

1 reference

Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.

31 March 2020

1 reference

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.

31 March 2020

1 reference

BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.

31 March 2020

1 reference

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

31 March 2020

1 reference

MEK1 mutations confer resistance to MEK and B-RAF inhibition

31 March 2020

1 reference

ERK inhibition overcomes acquired resistance to MEK inhibitors.

31 March 2020

1 reference

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

31 March 2020

1 reference

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma

31 March 2020

1 reference

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

31 March 2020

1 reference

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.

31 March 2020

1 reference

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

31 March 2020

1 reference

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

31 March 2020

1 reference

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

31 March 2020

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

31 March 2020

1 reference

600 Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors

31 March 2020

1 reference

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer

31 March 2020

1 reference

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

31 March 2020

1 reference

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

31 March 2020

1 reference

Improved overall survival in melanoma with combined dabrafenib and trametinib

31 March 2020

1 reference

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations

31 March 2020

1 reference

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

31 March 2020

1 reference

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

31 March 2020

1 reference

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

31 March 2020

1 reference

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

31 March 2020

1 reference

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers

31 March 2020

1 reference

A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens

31 March 2020

1 reference

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial

31 March 2020

1 reference

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

31 March 2020

1 reference

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

31 March 2020

1 reference

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

31 March 2020

1 reference

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

31 March 2020

1 reference

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

31 March 2020

1 reference

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

31 March 2020

1 reference

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

31 March 2020

1 reference

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.

31 March 2020

1 reference

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

31 March 2020

1 reference

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation

31 March 2020

1 reference

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

31 March 2020

1 reference

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

31 March 2020

1 reference

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

31 March 2020

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

The clinical development of MEK inhibitors

31 March 2020

1 reference

MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity

31 March 2020

1 reference

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

31 March 2020

1 reference

DNA methylation as a clinical marker in oncology

31 March 2020

1 reference

Genetic predictors of MEK dependence in non-small cell lung cancer

31 March 2020

1 reference

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

31 March 2020

1 reference

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies

31 March 2020

1 reference

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

31 March 2020

1 reference

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells

31 March 2020

1 reference

ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors

31 March 2020

1 reference

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF

31 March 2020

1 reference

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance

31 March 2020

1 reference

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

31 March 2020

1 reference

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.

31 March 2020

1 reference

The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier

31 March 2020

1 reference

Mathematical models of protein kinase signal transduction.

31 March 2020

1 reference

Information transfer by leaky, heterogeneous, protein kinase signaling systems

31 March 2020

1 reference

The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity.

31 March 2020

1 reference

Signalling ballet in space and time

31 March 2020

1 reference

A dimerization-dependent mechanism drives RAF catalytic activation

31 March 2020

1 reference

Regulation and role of Raf-1/B-Raf heterodimerization

31 March 2020

1 reference

Regulation of Raf-1 by direct feedback phosphorylation.

31 March 2020

1 reference

Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling

31 March 2020

1 reference

Strong negative feedback from Erk to Raf confers robustness to MAPK signalling.

31 March 2020

1 reference

Integrating signals from RTKs to ERK/MAPK.

31 March 2020

1 reference

Untangling the ErbB signalling network

31 March 2020

1 reference

Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism

31 March 2020

1 reference

A MEK-independent role for CRAF in mitosis and tumor progression.

31 March 2020

1 reference

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

31 March 2020

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

31 March 2020

1 reference

Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations

31 March 2020

1 reference

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

31 March 2020

1 reference

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer

31 March 2020

1 reference

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma

31 March 2020

1 reference

The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker.

31 March 2020

1 reference

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

31 March 2020

1 reference

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

31 March 2020

1 reference

Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer

31 March 2020

1 reference

Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma

31 March 2020

1 reference

Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours

31 March 2020

1 reference

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

31 March 2020

1 reference

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

31 March 2020

1 reference

TMEM16A alternative splicing coordination in breast cancer.

31 March 2020

1 reference

Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26399658

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRC4000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26399658%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

3 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26399658%20AND%20SRC:MED&resulttype=core&format=json